Healthcare & Life Sciences · PA
Eli Lilly breaks ground on $3.5 billion injectable medicines plant in Fogelsville, Pennsylvania.
The Lehigh Valley site is expected to be operational by 2031, with about 2,000 construction jobs and 850 permanent positions.
Quick answer
Eli Lilly and Company: $3.5 billion investment in Fogelsville, Pa. Stage: Under construction. Timeline: Announced Jan. 30, 2026. Groundbreaking Nov. 12, 2026. Expected to be operational by 2031. Likely to buy: cleanroom construction, process piping, mechanical and hvac, electrical.

By Capex Wire StaffPublished 2 min read
Eli Lilly and Company has broken ground on a $3.5 billion plant for injectable medicines in Fogelsville, Pennsylvania, in the Lehigh Valley, a project the company says will employ about 2,000 construction workers.
The groundbreaking took place Nov. 12, according to the company's announcement. The site is in Upper Macungie Township, in Lehigh County, and Lilly expects it to be operational by 2031.
The plant will make injectable medicines, including retatrutide, an investigational once-weekly obesity drug that is still in clinical trials and is not approved for sale. Lilly describes the site as one of four among its newly announced U.S. plants that are dedicated to injectable medicines and devices.
Jobs and schedule
- Investment: $3.5 billion
- Construction jobs: about 2,000
- Permanent jobs: about 850, including engineers, scientists, operations personnel and lab technicians
- Target for operations: 2031
The company is targeting LEED Gold certification for the site. Lilly said the plant will use machine learning, artificial intelligence, digitally integrated systems and advanced data analytics, with digital automation throughout.
"Obesity is one of the biggest health challenges of our time," David A. Ricks, Lilly chair and CEO, said in the announcement.
Capex Wire
Get there first: every project owner on the U.S. Project Map.
Hundreds of projects have not broken ground yet. See who is building each one, with address, design firm and source, before the bid list closes.
more than $126 billion
in announced or filed value
Subscribe for $9.90/monthCancel anytime in one click.
State support
Lilly first announced the project in January. At that time, Gov. Josh Shapiro's office said Pennsylvania was committing $100 million to the project. The package includes up to $50 million in tax credits through the PA Edge Tax Credit Program, a $25 million PA SITES grant, a $25 million Pennsylvania First grant and up to $5 million in Redevelopment Assistance Capital Program funding for workforce training. The state said the project is also receiving help through its PA Permit Fast Track Program.
Lilly also said it will provide up to $1 million over five years to the Upper Macungie Township Community Fund.
Part of a larger program
The Lehigh Valley plant is the latest of 10 new U.S. manufacturing sites Lilly has announced since 2020 and part of what the company calls a $50 billion push to expand U.S. medicine production. BioProcess International reported that the ceremony came weeks after Lilly broke ground on an oral GLP-1 manufacturing site in Houston.
What is not disclosed
Lilly has not named a general contractor, a construction manager, an architect or an engineering firm. The announcement does not give the size of the site in acres, the square footage of the buildings or a street address. No dates were given for bid packages, for mechanical completion or for the start of equipment installation. The company also did not break down how much of the $3.5 billion goes to construction and how much to process equipment.
- Owner
- Eli Lilly and Company
- Investment
- $3.5 billion (total investment, per company announcement)
- Location
- Fogelsville, Lehigh County, Pennsylvania
- Type
- Pharmaceutical plant, injectable medicines, new construction
- Stage
- Under construction
- Timeline
- Announced Jan. 30, 2026. Groundbreaking Nov. 12, 2026. Expected to be operational by 2031.
- Contractor / EPC
- Not announced
- Sources
- Eli Lilly and Company release via Finviz, BioProcess International, Trade & Industry Development, Office of the Governor of Pennsylvania
Why it matters
A $3.5 billion pharma plant with about 2,000 construction jobs and a 2031 target means years of cleanroom, process piping and mechanical work in the Lehigh Valley. No builder has been named, so suppliers should track who holds the construction management contract.
What this project buys
- Cleanroom construction
- Process piping
- Mechanical and HVAC
- Electrical
- Structural steel
- Concrete and foundations
When to approach: Ground broken Nov. 12, 2026. Builder not announced; identify the construction manager now, before major packages are awarded.
Typical scopes for a project of this type. This is an editorial estimate, not a list of awarded or advertised packages.
Sources
- Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020, Eli Lilly and Company release via Finviz, Nov. 12, 2026
- Lilly breaks ground on $3.5bn manufacturing site in Pennsylvania, BioProcess International, Nov. 13, 2026
- PA: Lilly Breaks Ground on $3.5B Lehigh Valley Site to Make Next-Generation Obesity Medicines, Trade & Industry Development, Nov. 16, 2026
- Governor Shapiro Secures Historic $3.5 Billion Investment from Lilly, Office of the Governor of Pennsylvania, Jan. 30, 2026


